Iqymune (Human Normal Immunoglobulin)

Iqymune is an intravenous immunoglobulin used to replace deficient antibodies in various immune‑mediated conditions.

• Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency.
• Secondary immunodeficiency: provides passive immunity when the patient’s own antibody production is compromised.
• Kawasaki disease: helps reduce coronary artery complications by modulating inflammation.
• Immune thrombocytopenic purpura (ITP): raises platelet counts through immune modulation.

• Human Normal Immunoglobulin supplies a broad spectrum of pooled IgG antibodies that bind and neutralize pathogens, opsonize microbes for phagocytosis, and modulate complement activation. The infused IgG also interacts with Fc receptors on immune cells, dampening auto‑antibody production and inflammatory cytokine release, thereby restoring immune balance in deficient or dysregulated states.

Adverse reactions can occur with any intravenous immunoglobulin product.

Common Side Effects

• Headache: mild to moderate, often transient.
• Fever or chills: typical infusion‑related response.
• Nausea or vomiting: gastrointestinal upset during or after infusion.
• Fatigue: feeling of tiredness post‑infusion.
• Myalgia: muscle aches that resolve within days.
• Hypertension or hypotension: blood pressure fluctuations during infusion.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: clot formation in veins or arteries.
• Acute renal failure: especially with high‑dose or rapid infusion.
• Aseptic meningitis: severe headache with meningeal signs.
• Hemolysis: destruction of red blood cells leading to anemia.
• Transfusion‑related acute lung injury (TRALI): respiratory distress shortly after infusion.

Before administering Iqymune, consider the following safety measures.

• Screen for IgA deficiency: patients with anti‑IgA antibodies are at higher risk of anaphylaxis.
• Monitor renal function: ensure adequate hydration and avoid nephrotoxic co‑medications.
• Assess thrombotic risk: evaluate history of clotting disorders before high‑dose infusions.
• Observe for infusion reactions: start at a slower rate and watch for signs of hypersensitivity.
• Contraindicate in known severe allergic reactions to immunoglobulin products.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intravenous immunoglobulin can affect the activity or safety of several co‑administered drugs.

Major Interactions (Avoid)

• Live attenuated vaccines: may reduce vaccine efficacy and increase infection risk.
• Cytotoxic chemotherapy agents: can amplify immunosuppression and toxicity.
• High‑dose steroids: may mask signs of infection during therapy.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may alter INR and increase bleeding risk.
• Diuretics: combined use can heighten renal impairment.
• ACE inhibitors: potential for additive hypotensive effects during infusion.